Home Newsfeeds Wedbush Maintains Neutral on Biogen, Raises Price Target to $247

Wedbush Maintains Neutral on Biogen, Raises Price Target to $247

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $218 to $247.

byBenzinga Newsdesk

November 30, 2022

1 minute read

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $218 to $247.

Leap Therapeutics To Present New Data From Part A Of The DeFianCe Study Of DKN-01 Plus Bevacizumab And Chemotherapy In Colorectal Cancer Patients At The 2024 ASCO Gastrointestinal Cancers Symposium

By Benzinga Newsdesk

December 11, 5:12 PM

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients

LPTX

Analyst Ratings

What 15 Analyst Ratings Have To Say About EOG Resources

By Benzinga Insights

September 1, 11:00 AM

Analysts have provided the following ratings for EOG Resources (NYSE:EOG) within the last quarter: Bullish Somewhat Bullish Indifferent…

EOG

Titanic Tourist Sub Missing: The Guinness Record-Holding Explorer Onboard, Sub’s Video Game Controller, Link To Blue Origin And More

By Chris Katje

June 20, 12:51 PM

A tourist sub set to take passengers to the wreckage of the Titanic in the deep ocean is missing. Here are the details on what we know as of Tuesday morning.

LOGI

Touchdown In Las Vegas: Exploring Nevada’s Cannabis Field, Market And Companies Ahead Of Super Bowl LVIII

By Nicolas Jose Rodriguez

February 9, 4:58 PM

As Super Bowl LVIII readies to get underway at Allegiant Stadium in Las Vegas this Sunday, Nevada's cannabis industry, underpinned by recent legislative reforms and strategic positioning, is set to capitalize on the influx of visitors.

AYRWF

Wedbush Maintains Neutral on Biogen, Raises Price Target to $247

Related Posts

Leap Therapeutics To Present New Data From Part A Of The DeFianCe Study Of DKN-01 Plus Bevacizumab And Chemotherapy In Colorectal Cancer Patients At The 2024 ASCO Gastrointestinal Cancers Symposium

What 15 Analyst Ratings Have To Say About EOG Resources

Titanic Tourist Sub Missing: The Guinness Record-Holding Explorer Onboard, Sub’s Video Game Controller, Link To Blue Origin And More

Touchdown In Las Vegas: Exploring Nevada’s Cannabis Field, Market And Companies Ahead Of Super Bowl LVIII